Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Arrowhead, Janssen ink new deals
December 2018
SHARING OPTIONS:

PASADENA, Calif.—Arrowhead Pharmaceuticals Inc. has shared news of a license and collaboration agreement with Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, under which the companies will develop and commercialize ARO-HBV. All told, Arrowhead stands to receive up to roughly $1.6 billion in milestone payments for the license agreement related to hepatitis B, with the potential for up to $1.9 billion in option and milestone payments linked to the collaboration agreement for up to three additional targets. Janssen will have a worldwide exclusive license to the ARO-HBV program, and after Arrowhead’s ongoing Phase 1/2 study, will be solely responsible for clinical development and commercialization. Janssen will have the option of choosing up to three new targets for which Arrowhead will develop clinical candidates to the point of IND filing, entirely funded by Janssen. Should Janssen exercise its option, it will assume responsibility for the candidates' clinical development and commercialization.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.